OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

drugsTreatmentPhase 3

Radotinib

aka Supect

Radotinib is an oral kinase inhibitor from Il-Yang Pharm. Co., Ltd., in registered phase 3 trials for chronic myeloid leukaemia.